Bevacizumab

證據等級: L5

預測適應症: 10 個

Bevacizumab: From Advanced Solid Tumors to Epiglottis Neoplasm

One-Sentence Summary

Bevacizumab (DB00112) is a recombinant humanized anti-VEGF-A monoclonal antibody, globally used as part of combination regimens for various VEGF-driven solid tumors. The TxGNN model predicts it may be effective for Epiglottis Neoplasm (its highest-scoring candidate, score 0.9990), but this evidence pack currently contains zero clinical trials and zero publications specific to this indication.

Quick Overview

Item	Content
Original Indication	Not available in evidence pack (`original_indications` empty; Finland: unmarketed, no license record)
Predicted New Indication	Epiglottis Neoplasm
TxGNN Prediction Score	99.90%
Evidence Level	L5
Finland Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack (original_moa: Data Gap DG002). Based on known information, bevacizumab is a monoclonal antibody that binds and neutralizes vascular endothelial growth factor-A (VEGF-A), blocking angiogenesis; it is globally used as part of combination chemotherapy regimens across a range of VEGF-driven solid tumors (e.g., metastatic colorectal cancer, non-squamous NSCLC, renal cell carcinoma, ovarian cancer, cervical cancer, glioblastoma). No Finland-specific marketing authorization exists in this evidence pack (market_status: 未上市 / Not Marketed, 0 licenses).

For epiglottis neoplasm specifically, the evidence pack contains no clinical trials or literature at all. The mechanistic rationale is limited to a class-level generalization: bevacizumab has been studied in other head-and-neck tumor sites (see related candidates below), and anti-VEGF therapy has a plausible biological rationale in head-and-neck squamous cell carcinomas broadly. However, for epiglottis neoplasm this remains an unverified extrapolation with no site-specific supporting data — the TxGNN score alone (99.90%) is not accompanied by any confirmatory trial or publication.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Finland Market Information

Bevacizumab is currently not marketed in Finland (total_licenses = 0; no license records on file).

Cytotoxicity

Bevacizumab is an antineoplastic agent (anti-VEGF monoclonal antibody used exclusively in oncology regimens), so this section applies.

Item	Content
Cytotoxicity Classification	Targeted therapy (anti-angiogenic monoclonal antibody; not a conventional cytotoxic chemotherapeutic)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score is high (99.90%), but there is no clinical trial or literature evidence specific to epiglottis neoplasm — evidence level is L5 (model prediction only), and this drug is not marketed in Finland.

To proceed, the following is needed:

Site-specific clinical trial or literature evidence for bevacizumab in epiglottis neoplasm
TFDA/Finland package insert warnings and contraindications (DG001, Blocking — currently missing)
Confirmed detailed mechanism of action data (DG002)
Verification that "epiglottis neoplasm" is a correctly mapped disease ontology term in the TxGNN prediction

Note: Within this same evidence pack, a lower-ranked candidate — cystic neoplasm (rank 7, TxGNN score 99.89%) — has substantially stronger supporting evidence (8 clinical trials including a Phase 3 RCT, 20 publications, Evidence Level L1, decision stage S3, recommendation "Proceed with Guardrails"), largely driven by bevacizumab's established use in low-grade serous ovarian cancer. That candidate may warrant separate evaluation as a higher-priority repurposing opportunity.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.